Wu Xuan, Chen Guorong, Yang Lu, Lv Zexun, Wu Yige, Liang Chuncai, Chen Yizhu, Shao Bing, Zhang Yanli, Li Hui
School of Public Health, Capital Medical University, Beijing 100069, PR China.
Beijing Key Laboratory of Diagnostic and Traceability Technologies for Food Poisoning, Beijing Center for Disease Prevention and Control, Beijing 100013, PR China.
Curr Res Microb Sci. 2025 Apr 30;8:100398. doi: 10.1016/j.crmicr.2025.100398. eCollection 2025.
The emergence of multidrug-resistant (MDR ), particularly enteropathogenic , is closely associated with therapeutic interventions for irritable bowel syndrome (IBS) and ulcerative colitis (UC) in clinical practice. However, a comprehensive characterization of their resistome differences remains limited. Exploring their resistance profiles and virulence gene repertoires is crucial for informing improved treatment strategies and controlling the dissemination of MDR in healthcare settings. Here, we analyzed 70 strains isolated from a single-center, case-control cohort enrolled between 2022 and 2023 at a tertiary care hospital in Beijing, China. Through integrated phenotypic and genomic approaches, we investigated their antimicrobial resistance (AMR) patterns and transmission dynamics. These strains exhibited high resistance to sulfonamides (34.3 %) and fluoroquinolones (32.9 %) in general. Incremental trends in β-lactam resistance were observed in the IBS-D and UC groups compared to the HC group, reflecting both phenotypic resistance and the presence of ESBL genes. Significant intergroup differences in the prevalence of β-lactam resistance gene , rifamycin resistance gene , and ExPEC-related nutritional/metabolic factors (e.g. ) were observed. Notably, the co-existence of and (X4) was first identified in IBS-D patients. The emergence of high-risk ST10, ST1193, and ST131 clones occurred in IBS-D and UC patients. Positive correlations were observed between the number of antibiotic resistance genes, virulence factor genes, and antibiotic usage history. This study underscores escalating AMR and virulence trends across patient groups and highlights the urgent need for tailored antimicrobial stewardship in managing IBS-D and UC.
多重耐药（MDR）菌的出现，尤其是肠道病原菌，在临床实践中与肠易激综合征（IBS）和溃疡性结肠炎（UC）的治疗干预密切相关。然而，对它们耐药组差异的全面表征仍然有限。探索它们的耐药谱和毒力基因库对于制定改进的治疗策略以及控制医疗环境中MDR菌的传播至关重要。在此，我们分析了从2022年至2023年在中国北京一家三级医院招募的单中心病例对照队列中分离出的70株菌株。通过综合表型和基因组方法，我们研究了它们的抗菌药物耐药（AMR）模式和传播动态。这些菌株总体上对磺胺类药物（34.3%）和氟喹诺酮类药物（32.9%）表现出高耐药性。与健康对照（HC）组相比，在IBS-D组和UC组中观察到β-内酰胺类耐药性呈上升趋势，这既反映了表型耐药性，也反映了ESBL基因的存在。观察到β-内酰胺类耐药基因、利福霉素耐药基因和与肠外致病性大肠杆菌（ExPEC）相关的营养/代谢因子（如）的患病率在组间存在显著差异。值得注意的是，首次在IBS-D患者中发现了和（X4）的共存。高风险的ST10、ST1193和ST131克隆出现在IBS-D和UC患者中。抗生素耐药基因数量、毒力因子基因数量与抗生素使用史之间存在正相关。本研究强调了各患者组中AMR和毒力趋势的不断升级，并突出了在管理IBS-D和UC时迫切需要制定针对性的抗菌药物管理措施。
